Venlafaxine Augmentation in Treatment Resistant Depression

• Status: Completed
• Trial end date: 2014-08-01
• Target enrollment: 0
• Participant gender: All

Summary

This is an assessment of the efficacy of venlafaxine-HCL augmentation with the neuroleptic quetiapine in treatment resistant depression.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Max-Planck-Institute of Psychiatry
• Treatments: Quetiapine Fumarate; Venlafaxine Hydrochloride

Criteria

Inclusion Criteria:

• Female and male inpatients with a major depressive disorder without psychotic features or with a depressive episode within a bipolar I or II disorder without psychotic features

• Ages between 20 and 70 years

• Total score greater than 18 on the Hamilton Depression Rating Scale

• Documentation of at least one ineffective antidepressant drug trial under adequate dosage for at least 6 weeks in the current episode

Exclusion Criteria:

• Other psychiatric axis I disorders than those mentioned as Inclusion criteria

• Acute suicidality (Item 3 of the Hamilton Depression Rating Scale greater than 2)

• Drug or alcohol addiction

• Patients with severe hepatic, cardiovascular, neurologic, metabolic or malignant disorders

• Documentation or report of a previous ineffective treatment trial with venlafaxine, lamotrigine or quetiapine

• Functional kidney disorders

• Untreated hypertension

• Acute treatment with thyroid hormone (less than 3 months)

• Pregnant or nursing patients

• Women of childbearing age without effective contraception